Hillel Bachrach is a dynamic executive entrepreneur with over 30 years of hands-on management, directorship & investor involved with all aspect of successful global commercial introductions of new, innovative and revolutionary medical technologies. His work led to significant sustained and profitable growth providing direct and positive impact on the valuation of the corresponding enterprise.
In 2005, Bachrach founded 20/20 HealthCare Partners LLC and continues to serve as its Managing Partner. 20/20 HCP owns and provides equity financing and management support for promising growth businesses as well as for buyouts or recapitalizations of companies specializing in the Healthcare IT, Big Data & AI, Diagnostic Imaging and the Biotech market place.
Bachrach co-founded ESC Medical, (now Lumenis), in 1993, the pioneer in medical laser/flash lamp technology addressing
aesthetic applications. ESC went public on NASDAQ in Jan 1996. In 1999 Bachrach, as an active director, co-founded MSq, Ltd, (now Alma Lasers), another innovator in the medical laser field. TA Associates, the private equity fund purchased 66% of the company in 2006 and Fuson, a Chinese pharmaceutical entity, purchased the entire company in 2013. Since early 2001, Bachrach served as President & CEO of Orex, successfully obtained VC funding in 2002 and led Orex Computerized Radiology to a turnaround leading to its eventual acquisition to Eastman Kodak by early 2005.
In 2006 20/20 HCP acquired a majority ownership in Viztek, a digital radiography & healthcare IT solutions provider. Bachrach served as Viztek’s active Chairman. Konica Minolta purchased Viztek in October 2015. Also in 2006, 20/20 HCP was the first institutional investor in Corindus Vascular Robotics, the pioneer of introducing robotics to the CathLab. Bachrach served on the BOD for 10 years while Corindus added Philips as a strategic investor, went public on NASDAQ (CVRS), and later moved to be traded on NYSE.
20/20 HCP lead by Bachrach experienced additional exits of its portfolio companies: Vascular Biogenics Lab Ltd, (NASDAQ-VBLT), Odin Medical Technologies (sold to Medtronic), Intec Pharma (NASDAQ-NTEC), Topokine (sold to Allergan).
Recent 20/20 HCP investments include 2 Biotech entities sprung from Dr. Robert Langer MIT lab – SQZ Biotechnologies & Verseau Therapeutics.
20/20 HCP continues its support, funding and active BOD participation, to its portfolio investments.
Bachrach and his wife are also involved/support the Boston Symphony Orchestra, The Whitehead Institute, Harvard Kennedy School Belfer Center, MIT Deshpande Center & Boston Children Hospital, among others.
Bachrach received his MBA from Kellogg Graduate School of Management in 1976 and B.Sc. in Electrical Engineering from the Technion Israeli Institute of Technology in 1971.
Christine is a serial Entrepreneur, Founder & Former CEO of two Life Science Companies: INTICA Biomedical (Personalized Medicine/Cancer) and TARIS Biomedical. TARIS (www.tarisbiomedical.com), acquired by Allergan in 2014,was co-founded with Prof. Michael Cima and Prof. Robert Langer from MIT, Cambridge, MA. Christine is a Venture Partner and Entrepreneur in Residence with 20/20 HealthCare Partners, a private global investment group. Previously, Christine was with Merck & Co. in Whitehouse Station, NJ, where she was leading worldwide Commercialization for Inflammation, Neuroscience and Cardiovascular Products. Prior to Merck & Co., Christine assumed various R&D, Business Management and Commercialization Functions at Hoffmann- La Roche in Basel, Switzerland. Christine got her Degree’s in Medical Technology & Immunochemistry (Biochemistry) from the Institute for Hygiene and Infectious Diseases / Medical School of the University of Saarbrücken, Germany.
Christine mentors Entrepreneurs/new Technology start-up’s at the MIT Deshpande Center. She serves on the Board of the Beth Israel Deaconess Medical Center (BIDMC) and on the Advisory Board of the BIDMC Cancer Research Center. Christine is a German native with German Jewish & Catalan family background from Barcelona, Spain. She grew up in the Netherlands, Belgium, France and Germany. Christine lives with her husband and two children in Lexington, MA. Christine is a dedicated “Yogi” and enjoys outdoor activities including sailing, running and skiing.
Jonathan Fleming is the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments He is also a General Partner of the Korea-Seoul Life Science Fund.
Mr. Fleming has been in the investment business for over twenty seven years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming is a director of several private companies including Dicerna Pharmaceuticals, Lab Partners, Greenlight and Railrunner. He is also a director of Leerink Swann, a Boston based investment bank specializing in healthcare companies. In addition, Mr. Fleming is a Senior Lecturer at the MIT Sloan School of Business, a Lecturer at the Harvard Medical School, a Trustee of the Museum of Science in Boston, and a Member of the Board of NEHI, a healthcare oriented think tank and policy advocacy group. Mr. Fleming is on the Scientific Advisory Board of the Massachusetts Life Science Center, and is a member of the Barnett Institute Advisory Board as well as the Chancellor’s Commercialization Advisory Board of the University of Texas System. Mr. Fleming holds a Master’s degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.
Walter M. Capone
Walter is an accomplished, global Biotech/Pharma leader with a twenty year track record of accelerating breakthrough
science, drug development and commercialization. His therapeutic experience spans the immunology, oncology and infectious disease areas. From 2010-2016, he was CEO & President of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC), where he transformed the Foundation to leverage industry
experience, academic research and FDA collaborations, resulting in 50% revenue growth to >$30M, a record 6 new
drugs approved/launched and a >4-fold expansion in academic/industry partnerships. In his roles as SVP
Commercial Operations, VP Commercial Development, and Division Manager for Progenics, Triangle Pharmaceuticals,
Trimeris, BMS, Wyeth and Lederle, Walter has led the development and launch of over 18 novel drugs including
FUZEON®, EMTRIVA®, TEQUIN®, ZERIT®, VIDEX®, and ZOSYN®.
Walter obtained his M.B.A. from Columbia University and B.A. from Brown University.
Ronny Vinasco Bachrach
Ronny Bachrach’s experience includes childhood development, as well as research of Alzheimer’s Disease and Semantic Dementia. Bachrach graduated cum laude from Colby College with distinction in psychology.